Human mesenchymal stem cells (MSCs) are multipotential and are detected in bone marrow (BM), adipose tissue, placenta, and umbilical cord blood (UCB). In this study, we examined the ability of UCB-derived MSCs (UCB-MSCs) to support ex vivo expansion of hematopoietic stem/progenitor cells (HSPCs) from UCB and the engraftment of expanded HSPCs in NOD/SCID mice. The result showed that UCB-MSCs supported the proliferation and differentiation of CD34 + cells in vitro. The number of expanded total nucleated cells (TNCs) in MSC-based culture was twofold higher than cultures without MSC (control cultures). UCB-MSCs increased the expansion capabilities of CD34 + cells, long-term culture-initiating cells (LTC-ICs), granulocyte-macrophage colony-forming cells (GM-CFCs), and high proliferative potential colonyforming cells (HPP-CFCs) compared to control cultures. The expanded HSPCs were transplanted into lethally irradiated NOD/SCID mice to assess the effects of expanded cells on hematopoietic recovery. The number of white blood cells (WBCs) in the peripheral blood of mice transplanted with expanded cells from both the MSC-based and control cultures returned to pretreatment levels at day 25 posttransplant and then decreased. The WBC levels returned to pretreatment levels again at days 45-55 posttransplant. The level of human CD45 + cell engraftment in primary recipients transplanted with expanded cells from the MSC-based cultures was significantly higher than recipients transplanted with cells from the control cultures. Serial transplantation demonstrated that the expanded cells could establish long-term engraftment of hematopoietic cells. UCB-MSCs similar to those derived from adult bone marrow may provide novel targets for cellular and gene therapy.
INTRODUCTION
engraftment of donor hematopoietic cells after cotransplantation in animal models (1) (2) (3) . MSCs are also present at low frequencies in adult peripheral blood (28) and Adult human bone marrow contains a rare population of mesenchymal stem cells (MSCs) that can be exten-in umbilical cord blood (UCB) (8, 11, 24, 27) . UCBderived MSCs (UCB-MSCs) have a similar phenotype sively ex vivo expanded and, when cultured under specific permissive conditions, retain their ability to differ-to the adult bone marrow-derived MSC and produce stem cell factor (SCF), interleukin-6 (IL-6), and tumor entiate into multiple lineages including bone, cartilage, tendon, muscle, nerve, and stromal cells (6, 9, (17) (18) (19) 25) .
necrosis factor-α (TNF-α) (24) . Here we used UCB-MSCs to study their potential to support ex vivo expan-MSCs are of great therapeutic potential because of their ability to self-renew and differentiate into multiple tis-sion of CD34 + hematopoietic stem/progenitor cells (HSPCs) from UCB. Transplantation of expanded sues (10) . Adult bone marrow-derived MSCs enhance 580 HUANG ET AL.
HSPCs into NOD/SCID mice was performed to demon-factor (rhSCF), recombinant human granulocyte colonystimulating factor (rhG-CSF), and recombinant human strate the engraftment potential of HSPCs expanded by UCB-MSCs. megakaryocyte growth and development factor (rhMGDF) (Amgen Inc., Thousand Oaks, CA), and then seeded at MATERIALS AND METHODS a density of 1.6 × 10 4 cells/cm 2 into 25-cm 2 flasks with Isolation and Culture of Mesenchymal Stem Cells or without the UCB-MSCs. The CD34 + cells were cul-(MSCs) From Umbilical Cord Blood (UCB) tured in 100% humidified 5% CO 2 in air at 37°C. At the beginning (the first day) and the ending (the 12th day) UCB products for research purposes were kindly proof culture, nonadherent cells in the culture medium were vided by the Obstetrics Department of the Hangzhou assayed for granulocyte-macrophage colony-forming Traditional Chinese Medical Hospital. Parturient women cells (GM-CFC) in complete methylcellulose without gave written consent for the use of UCB for research erythropoietin (Gencyte, Anherat, NY) (24) . purposes.
UCB-MSCs were isolated and cultured as previously Long-Term Culture-Initiating Cell Assay described (24) , with a slight modification. Briefly, hepa-(LTC-IC Assay) rinized UCB was centrifuged at 450 × g for 10 min. The LTC-IC assay was performed as described by Xie et pellet was diluted with α-minimum essential medium al. (26) , with slight modifications. Briefly, UCB-MSCs (α-MEM; Gibco BRL, Life Technologies, Paisley, UK)
were seeded at a density of 4 × 10 3 cells per well in 96and then layered onto Ficoll-Hypaque (1.077 ± 0.001 well flat-bottomed plates (Costar) with α-MEM suppleg/ml; Sigma, St. Louis, MO), and centrifuged at 300 × mented with 10% FBS. After semiconfluence, CD34 + g for 20 min. The low-density mononuclear cells cells purified from UCB or expanded cells by sorting (MNCs) from the gradient interface were collected and with a FACSVantage (Becton Dickinson, San Jose, CA) washed three times with α-MEM and then diluted with were seeded at limiting dilution on the feeder layer in complete medium [10% fetal bovine serum (FBS;
IMDM with 20% FBS. For each evaluation, at least Sigma) in α-MEM with 50 µM 2-mercaptoethanol, 2 three cell concentrations were used with 24 replicates mM L-glutamine, and 1 µM hydrocortisone sodium sucper concentration. Culture plates were incubated at 37°C cinate (Gibco BRL)]. The resuspended cells were placed with 5% CO 2 with weekly media change. After 5 weeks into 25-cm 2 flasks (Costar, Bethesda, MD) at a density of culture, cells were assayed for GM-CFC. Colonies of 4.2 × 10 5 cells/cm 2 , and incubated in 100% humidiwere scored 2 weeks later. The frequency of wells in fied 5% CO 2 in air at 37°C. When adherent cells were which there were no clonogenic progenitors was deterpresent, the supernatant and nonadherent cells were remined according to the number of the initial input popumoved, and the complete medium replaced. At 90% lation. Poisson statistics was applied to the single-hit confluence, cells were harvested with 0.25% trypsin and model and the frequency of LTC-ICs was calculated 1 mM EDTA (Stem Cells Technology, Vancouver BC, with the maximum likelihood estimator. Canada). Harvested cells were sorted labeled with anti-CD34, and the CD34 + cells were depleted using a Engraftment Assay of Expanded HSPCs in NOD/SCID MACS laboratory separation system (Miltenyi Biotec, Serial Transplantation Bergisch Gladbach, Germany) according to the manu-
The transplantation of expanded cells from MSCfacturer's instructions. The CD34 − cells were diluted based cultures and control cultures into NOD/SCID with complete medium and placed into 25-cm 2 flasks at mice was performed as previously described (4), with a density of 5 × 10 3 cells/cm 2 , and then incubated in slight modifications. Briefly, 8-week-old male NOD/ 100% humidified 5% CO 2 in air at 37°C as the F 1 pas-SCID mice were obtained from the Central Institute for sage. At near confluence, cells were harvested and pas-Experimental Animals, Shanghai Institutes for Biologisaged using the same protocol.
cal Sciences, CAS. All animals were handled under ster-Coculture of UCB-MSCs and CD34 + Hematopoietic ile conditions and maintained under microisolators in the Stem/Progenitor Cells (HSPCs) From UCB animal facility located at Zhejiang Academy of Medical Sciences. At 24 h before transplantation, NOD/SCID MNCs from UCB were isolated as above. CD34 + cells were selected from the MNC preparations with mice were irradiated with a 60 Coγ in a split dose with a 4-h interval between doses. Each dose consisted of 15 anti-CD34 antibodies (Miltenyi Biotec) conjugated with microbeads and eluted through MiniMACS columns ac-min at 14.5 r/min. The expanded cells were transplanted by tail-vein injection into the irradiated NOD/SCID cording to the manufacturer's instructions. The CD34 + cells were resuspended in Iscove's modified Dulbecco's mice. Group A (N = 18 mice) was transplanted with cells from MSC-based culture, group B (N = 18 mice) medium (IMDM; HyClone, Logan, UT) with 20% FBS and 100 ng/ml each of recombinant human stem cell was transplanted with cells from control culture, and group C (N = 18 mice) was injected with the same volume (200 µl) of PBS/1% HAS (irradiation control). The number of transplanted cells for each irradiated mouse was 8.8 × 10 5 cells in 200 µl suspension. Starting on day 2 posttransplant, 100 µl peripheral blood was collected by retro-orbital sampling from each mouse and at subsequent regular intervals. The peripheral blood was diluted up to 250 µl with PBS/1% HSA, and then analyzed for hematopoietic recovery using Advia 120 (Bayer, Leverkusen, Germany). Primary recipients were killed 8 weeks after transplantation, and the bone marrow (from the femurs and tibiae) was harvested. Total marrow cells (12 × 10 6 ) from the primary recipients with engraftment levels >15% in groups A The cell products harvested after 12 days had signifi-Statistics cantly higher percentages of CD15 + and CD14 + mature Results are expressed as mean ± SEM, and statistical myeloid cells ( Table 1 ). The percentages of CD15 + and comparisons were performed using the Student t-test.
CD14 + cells were 49% and 12%, respectively, for coculture scheme, and 55% and 19%, respectively, for nonco-RESULTS culture scheme.
The Ability of UCB-MSCs to Support Ex Vivo
The percentage of CD34 + cells decreased after 12 Expansion of Hematopoietic Stem/Progenitor Cells days of expansion (4.6% and 2.4%, respectively, for MSC-based and control cultures compared to the start-To determine whether UCB-MSCs were capable of ing percentage of 97.9% for CD34 + cell fraction). CD34 + supporting the ex vivo proliferation and differentiation cells in MSC-based cultures, however, were expanded of HSPCs, confluent monolayers of UCB-MSCs (pasapproximately 4.0-fold (from 3.92 ± 0.44 × 10 5 CD34 + sage F 5 , n = 5) were used for coculture of human UCB cells in the starting culture time to 0.15 ± 0.02 × 10 7 CD34 + cells. CD34 + cells were overlaid and maintained CD34 + cells in the ending culture time) (p < 0.01). in culture for up to 12 days. As controls, UCB CD34 + cells were seeded into the 25-cm 2 flask with the same LTC-IC Assay Using the CD34 + Population Isolated medium but without UCB-MSCs. Growth kinetics of the From Expanded Cells nonadherent cells are shown in Figure 1 . The total nuclear cells (TNCs) in MSC-based cultures were ex-To determine whether the cells generated in the two culture conditions could sustain the ability of long-term panded 79.6 ± 5.7-fold, from 4 × 10 5 cells at the start of culture to 3.2 ± 0.20 × 10 7 cells at the end of culture, hematopoiesis, the LTC-IC frequency in the expanded cells was quantified. Initially, isolated UCB CD34 + cells and this was 2.11 ± 0.7-fold higher (p < 0.01) than the TNCs in control cultures, which were expanded 37.7 ± were cultured for 12 days. The expanded cells were harvested and subjected to a second CD34 + cell purification 4.2-fold, from 4 × 10 5 cells at the start of culture to 1.5 ± 0.17 × 10 7 cells at the end of culture.
by sorting. LTC-IC assay was performed using sorted CD34 + cells, as well as those initially prepared from GM-CFC assays were performed with nonadherent cells at the beginning (the first day) and the termination UCB (control samples). The LTC-IC frequency was determined as previously described (26) . As shown in Ta-(the 12th day) of culture. As shown in Figure 2 The finding suggests that the MSC-based culture condi-45-55th days) between the cells from the MSC-based and control cultures (p > 0.05). tion might be a novel as well as efficient culture scheme for UCB-derived hematopoietic progenitor cells.
Eight weeks after transplantation, human CD45 + cells were detected in the bone marrow of primary recipients
Effects of the MSC-Based Culture as Feeder Layers
transplanted with the expanded cells. There was a signifof Human Reconstituting Hematopoietic Progenitors icant difference of human CD45 + cell engraftment level in the bone marrow between primary recipients trans-Accordingly, we determined the engraftment potential of the expanded cells in vivo. Cells expanded for 12 planted with cells from the MSC-based and control cultures (46.3 ± 11.6% for group A and 21.7 ± 6.8% for days were transplanted into NOD/SCID mice. All mice in the irradiation control group (group C) were dead group B, p < 0.01). Furthermore, PCR analysis demonstrated the presence of human hematopoietic cells in the within 13 days. For the mice transplanted with expanded cells from control cultures (group B), three mice died at bone marrow of NOD/SCID mice transplanted with expanded cells (Fig. 4 ). the 12th, 16th, and 17th day after transplantation, respectively. For the mice transplanted with expanded To examine the engraftment potential of expanded cells in serial transplantation, total marrow cells (12 × cells from MSC-based cultures (group A), one mouse died at the 23rd day after transplantation. The number 10 6 ) from primary recipients with engraftment levels >15% were serially transplanted into secondary recipi-of WBC in mice transplanted with expanded cells began to increase around day 15 posttransplant. The number of ents. At 8 weeks posttransplant, the percentage of secleucocytes reached baseline pretreatment levels at day 25 posttransplant and then decreased significantly. This Table 2 . Results of LTC-IC Assay Using UCB CD34 + Cells number returned to the pretreatment level again at or Those Generated by Five Culture Systems around days 45-55 posttransplant (Fig. 3) ondary recipients with an engraftment level higher than marrow whereas the other five recipients displayed higher engraftment at 11.54-27.33%. 0.2% was 72.2% (13:18) in group A and 44.4% (8:18) in group B. The analysis of human CD45 + cells in the DISCUSSION bone marrow of secondary recipients revealed the average engraftment level of 22.4 ± 11.1% (0.29-46.58%, By the specific culture conditions, it has been demonstrated that human UCB can be routinely cultured to n = 13) in group A and of 13.6 ± 9.9% (0.24-27.33%, n = 8) in group B. There was no significant difference form a confluent adherent feeder layer (8, 11, 24, 27) . Our previous studies demonstrated that the morphology and in engraftment levels between secondary recipients in group A and group B (p > 0.05). Five of 13 secondary immunophenotype of UCB-MSCs were similar to that of adult bone marrow-derived MSCs (24) . UCB-MSCs, recipients in group A showed 0.29-6.1% human CD45 + levels in the bone marrow whereas the other eight recipi-like adult bone marrow-derived MSCs, have the functional property of supporting proliferation of HSPCs in ents displayed markedly higher engraftment at 10.28-46.58%. Three of eight secondary recipients in group B vitro (27) . In this study we demonstrated that UCB-MSCs could effectively support ex vivo expansion of showed 0.24-0.72% human CD45 + levels in the bone UCB-HSPCs in synergy with human cytokines. The CD45 + cells in the bone marrow of primary recipients. In this experiment, we used primary recipients with en-present results showed that there were significant differences in TNC, CD34 + cells, GM-CFC, and HPP-CFC graftment levels >15% for the second transplantation. It was found that the percentage of secondary recipients expansion between the MSC-based and control cultures over a 12-day period. The MSC-based cultures enhanced with the engraftment level >0.2% in group A was higher than that in group B. It should be that the engraftment generation of TNCs, GM-CFC, HPP-CFC, and CD34 + cells, and especially supported the expansion of LTC-level difference of human CD45 + cells in the bone marrow of primary recipients between group A and group IC. Therefore, it may be possible to use these expanded cells as a source of blood transfusion after differentia-B resulted in the difference of rapid engraftment in secondary recipients. However, the engraftment level dif-tion of the expanded cells into megakaryocytes or erythroblast progenitor cells (13) .
ference of human CD45 + cells in the bone marrow of secondary recipients between group A and group B was Hematopoietic growth factors and cytokines play a critical role in the proliferation and differentiation of not significant. It remains to be studied whether there was a difference in the level of hematopoietic progeni-HSPCs. In adult bone marrow, mesenchymal cells provide signals for differentiation and proliferation of he-tors (such as CD34 + cells) in the bone marrow of primary recipients between group A and group B, to which matopoietic stem cells and their progeny through direct cell-cell interactions (27) and secretion of hematopoi-the engraftment level difference of human CD45 + cells in secondary recipients should be relative. etic growth factors and cytokines (7, 12, 15) . It has been demonstrated that proliferation and differentiation of Cotransplantation of adult MSCs is capable of enhancing engraftment of hematopoietic stem cells in a fe-HSPCs occurs in a number of histologically distinct microenvironments [yolk sac (20), ventral aorta (21), fetal tal sheep model (1) (2) (3) , which suggests that cotransplantation of MSCs and HSPCs from human UCB results in liver, thymus, spleen, and bone marrow (16) ] during human ontogeny. SCF, IL-6, and TNF-α were detected in acceleration of rapid, middle, and long engraftments of HSPCs. It has been suggested that 40% UCB is used to the conditioned medium of UCB-MSC cultures (24) . TNF-α can induce cells to express mRNAs of many he-ex vivo expansion and another 60% UCB is unexpanded, and then the mixture of expanded cells and un-matopoietic factors, such as IL-1, IL-6, IL-8, and GM-CSF (23) . Coordinate regulation of various growth fac-expanded cells is used as transplants during clinical transplantation of UCB (14) . For patients receiving a tors produced or induced by UCB-MSCs in coculture scheme may support ex vivo proliferation and differenti-high dose of chemotherapy, it not only eliminated the potential risk of extended neutropenia by expanded ma-ation of human UCB-HSPCs. The ex vivo expansion potential of HSPCs in the MSC-based cultures was, in-ture progenitor cells but also provided a long-term hematopoietic reconstitutation by more primitive stem deed, higher than that in the control cultures, although exogenous SCF, G-CSF, and MGDF were similarly used cells, such as MSCs, supporting proliferation and differentiation of HSPCs in vivo. It will be interesting to co-in both conditions. Therefore, it is inferred that other hematopoietic growth factors and cytokines detected and transplant UCB-MSCs with expanded HSPCs into a NOD/SCID mouse model for studying the function of undetected by us may play an important role in ex vivo expansion of HSPCs.
UCB-MSCs to support the proliferation and differentiation of HSPCs in vivo. Previous findings demonstrated that LTC-ICs from UCB were present in the CD34 + cell fraction (5, 22) . Fur-In conclusion, the use of UCB-MSCs as a feeder layer in the culture system is an alternative approach for thermore, it was identified that human SCID-repopulating cells (SRC) were capable of multilineage reconsti-ex vivo expansion of hematopoietic stem cells. This will allow investigators to more effectively study mecha-tution in the bone marrow of NOD/SCID mice (4) . Therefore, the expanded hematopoietic progenitors were nisms of cell development, maintenance, and differentiation of HSPCs. In addition, the ex vivo expansion of expected to sustain long-term hematopoiesis. As a result, more than fivefold LTC-IC amplification was observed CD34 + cells on an autologous feeder layer will be far superior to that on a bone marrow-derived adherent in cells expanded by the MSC-based culture. The SRC assay indicated the reconstituting ability of these ex-layer because it can avoid the possibility of allogeneic cell contamination. panded HSPCs. The engraftment level of human CD45 + cells in primary recipients transplanted with cells from
